Now Playing
Opinion|Videos|September 30, 2024
Clinical Impressions and Therapy Goals
Author(s)Joshua K. Sabari, MD
Panelists discuss how managing extensive stage small cell lung cancer involves balancing the survival benefits of subsequent therapies with the risks of treatment-related adverse events, emphasizing the importance of individualized treatment strategies.
Episodes in this series
Video content above is prompted by the following:
Describe the case and your initial impressions:
- What would be the predominant goals of therapy for a patient such as this?
- In patients with extensive stage small cell lung cancer (ES-SCLC) that has progressed, how do you balance the survival benefits afforded by subsequent lines of therapy with risks of treatment-related adverse events after progression of disease on platinum-based primary therapy?
- For primary therapy of ES-SCLC, under what circumstances would you consider extending the cycles of chemoimmunotherapy from 4 to 6?
